Thus, our results demonstrate that the expression of CB1 and/or CB2 receptors predispose glioma cells to cannabinoid-induced cell death, while TP53 and/or PTEN defects did not abrogate the pro-apoptotic responses induced by the treatment. The gene discussed is PTEN; the disease is central nervous system cancer.